NSK-01105, a Novel Sorafenib Derivative, Inhibits Human Prostate Tumor Growth via Suppression of VEGFR2/EGFR-Mediated Angiogenesis

The purpose of this study is to investigate the anti-angiogenic activities of NSK-01105, a novel sorafenib derivative, in in vitro, ex vivo and in vivo models, and explore the potential mechanisms. NSK-01105 significantly inhibited vascular endothelial growth factor (VEGF)-induced migration and tube...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Pengfei, Ye, Liang, Wang, Hongbo, Du, Guangying, Zhang, Jianzhao, Zuo, Yanhua, Zhang, Jinghai, Tian, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281216/
https://www.ncbi.nlm.nih.gov/pubmed/25551444
http://dx.doi.org/10.1371/journal.pone.0115041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281216/
https://www.ncbi.nlm.nih.gov/pubmed/25551444
http://dx.doi.org/10.1371/journal.pone.0115041

Ejemplares similares